Giuliana Grossi

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.

Phase 3 TRANSCEND shows setmelanotide cuts BMI and hunger in acquired hypothalamic obesity, signaling a new targeted option after hypothalamic injury.

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

Racial gaps in cancer pain care; CGT program reimbursement hurdles; FIB4 liver screening underused; OCM legacy debated; MM bispecifics face access gaps.

A meta-analysis of 39 studies found similar or slightly better cancer survival for Black veterans compared with White veterans in the VHA.

FDA approves Orca-T precision Treg cell therapy for matched donor transplants, cutting chronic GVHD risk and boosting survival in blood cancers.

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.

Longer sleep is linked to lower glycemic variability and reduced deviation risk in adolescents; higher daytime variability predicted shorter subsequent sleep.

Obesity coding gaps limit care; MCL rising in women; racial pain disparities in oncology; AML access expands; SDOH rivals genetics.

An MRI study found hypothalamic atrophy across most subregions in adults with narcolepsy type 1, with the tuberal-inferior region relatively spared.

Those with class III obesity showed 7%+ weight loss with high engagement; Stephanie Kim, MD, MPH, talks GLP-1 complementarity and prospective study needs.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

Fear of CPAP deters patients with OSA from seeking care. Experts call for early diagnosis with oral devices and warn payers about the cost of delays.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

The FDA issued a CRL for cytisinicline's NDA over manufacturing deficiencies at a third-party facility, with no efficacy or safety concerns cited.

Texas abortion ban worsens maternal mental health; SCD trials exclude 90% of adults; nutrition, hepatitis B, and cost-control gaps persist.

A new study finds Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve.

Referral hurdles, months-long sleep testing waits, and CPAP reluctance delay OSA care; at-home screening and oral appliances expand access.

ACP's new obesity guidelines name semaglutide and tirzepatide as first-line drugs in a 4-tier hierarchy, with weight-regain warnings for all agents.

In a VESALIUS-CV subgroup analysis, evolocumab cut MACE by 29% in high-risk diabetes, reinforcing intensive LDL lowering for CV risk reduction.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

ACA cancellations rise; HBV re-engagement varies by outreach; rural US has 44% fewer clinicians; diabetes and alopecia need custom care.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

The CHG index predicted CKM syndrome onset, progression, and adverse outcomes, suggesting a simple tool for risk stratification across disease stages.

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

Research from Samuel Shangwu Wu, PhD, presented as an ADA Presidents' Select Abstract, proposes a better way to measure beta-cell preservation.

Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.